Dexcom

{{Infobox company

| name = DexCom, Inc.

| type = Public

| traded_as = {{ubl|class=nowrap|{{NASDAQ|DXCM}}|Nasdaq-100 component|S&P 500 component}}

| location = {{nowrap|San Diego, California, U.S.}}

| key_people = Kevin Sayer (chairman, president & CEO)

| products = Medical devices

| foundation = {{start date and age|1999}}

| revenue = {{increase}} {{US$|4.03 billion|link=yes}} (2024)

| operating_income = {{increase}} {{US$|600 million}} (2024)

| net_income = {{increase}} {{US$|576 million}} (2024)

| assets = {{increase}} {{US$|6.48 billion}} (2024)

| equity = {{increase}} {{US$|2.10 billion}} (2024)

| num_employees = 10,300 (2024)

| website = {{URL|dexcom.com}}

| logo = Dexcom logo.svg{{!}}class=skin-invert-image

| footnotes = {{Cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/1093557/000109355725000036/dxcm-20241231.htm |title=2024 Annual Report (Form 10-K) |date=February 18, 2025 |publisher=U.S. Securities and Exchange Commission}}

}}

DexCom, Inc.{{cite press release |url=https://www.businesswire.com/news/home/20220425006053/en/DexCom-Showcases-Expanded-CGM-Portfolio-at-International-ATTD-Conference-Offering-More-Choice-to-People-With-Diabetes |title=DexCom Showcases Expanded CGM Portfolio at International ATTD Conference, Offering More Choice to People with Diabetes |date=26 April 2022 }} is an American healthcare company that develops, manufactures, produces, and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California; and has manufacturing facilities in Mesa, Arizona; Batu Kawan, Malaysia; and Athenry, Ireland.

History

Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel.{{Cite web|url=https://www.bizjournals.com/phoenix/news/2017/04/14/dexcom-adding-500-jobs-in-mesa.html|title=Dexcom adding 500 jobs in Mesa|website=www.bizjournals.com|access-date=September 19, 2019}}{{Cite web|url=https://www.sandiegouniontribune.com/business/biotech/sdut-freedom-meditech-2013aug06-story.html|title=Freedom Meditech raises $7 million|date=August 7, 2013|website=San Diego Union-Tribune|language=en-US|access-date=September 19, 2019}} In 2006, Dexcom received U.S. Food and Drug Administration (FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second generation product, the Seven Continuous Glucose Monitoring System, in May 2007. This device improved on accuracy and extended use from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation{{cite web|url=http://investor.shareholder.com/dexcom/releasedetail.cfm?ReleaseID=285480|title=Insulet Corporation and DexCom Announce Development Agreement (NASDAQ:DXCM)|work=Investor.shareholder.com|date=January 7, 2008|access-date=December 3, 2015|archive-date=December 8, 2015|archive-url=https://web.archive.org/web/20151208060344/http://investor.shareholder.com/dexcom/releasedetail.cfm?ReleaseID=285480|url-status=dead}} and Animas Corporation{{cite web|url=http://investor.shareholder.com/dexcom/releasedetail.cfm?ReleaseID=286182|title=DexCom™ Announces Joint Development Agreement with Animas Corporation|work=Investor.shareholder.com|date=June 10, 2008|access-date=April 4, 2016|archive-date=March 18, 2016|archive-url=https://web.archive.org/web/20160318123026/http://investor.shareholder.com/dexcom/releasedetail.cfm?ReleaseID=286182|url-status=dead}} as well as a development agreement with Edwards Lifesciences for a continuous glucose monitor in the intensive care unit hospital environment.{{cite web|url=http://investor.shareholder.com/dexcom/releasedetail.cfm?ReleaseID=346852|title=Edwards Lifesciences and DexCom to Develop Continuous Glucose Monitoring Products for Hospital Market (NASDAQ:DXCM)|work=Investor.shareholder.com|date=November 10, 2008|access-date=December 3, 2015|archive-date=December 8, 2015|archive-url=https://web.archive.org/web/20151208082139/http://investor.shareholder.com/dexcom/releasedetail.cfm?ReleaseID=346852|url-status=dead}}

During February 2009, Dexcom received approval for the Seven Plus Continuous Glucose Monitor, its new continuous glucose monitoring system, from the FDA. This product received a CE mark in November 2009. In 2013, development work for integration with Insulet was discontinued. Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its forthcoming G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps.{{cite web|url=http://www.prnewswire.com/news-releases/tandem-diabetes-care-announces-development-agreement-with-dexcom-for-integration-of-future-generation-cgm-systems-300121513.html|title=Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems|work=PR Newswire|date=July 30, 2015|access-date=December 3, 2015}} The G5 was approved in 2016 by the FDA for use as a standalone device, while the G6 gained approval in 2018.{{Cite press release|title=FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices|date=March 27, 2018|publisher=FDA|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm602870.htm|archive-url=https://web.archive.org/web/20180327222608/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm602870.htm|url-status=dead|archive-date=March 27, 2018|access-date=March 27, 2018}}

Dexcom's first G-series CGM, the G4 Platinum, received a CE mark{{Cite web |date=11 October 2012 |title=FDA Nod for Dexcom G4 Platinum - Analyst Blog |url=https://www.nasdaq.com/articles/fda-nod-for-dexcom-g4-platinum-analyst-blog-2012-10-11 |website=Nasdaq |publisher=Zacks}} and FDA approval in 2012 for adults ages 18 and over. This device improved hypoglycemic accuracy by 30%. It also offered a longer range of transmission between the sensor and receiver, as well as a color LCD.{{Cite web|url=https://www.fool.com/investing/2018/06/13/dexcom-stock-history.aspx|title = DexCom Stock History|date = 13 June 2018}} The G4 Platinum was approved by the FDA for use in patients ages 2–17 in February 2014.{{Cite web|url=https://diatribe.org/issues/61/new-now-next/2|title=FDA Approves Pediatric Use for Dexcom's G4 Platinum CGM|date=19 February 2014}} Dexcom received FDA approval in January 2015 for the G4 Platinum with Share, which enabled the sharing of CGM data with up to five other people using the "Share" and "Follow" smartphone apps.{{Cite web |date=January 29, 2015 |title=Dexcom G4 Platinum With SHARE Gets FDA Approval |url=https://www.diabetesincontrol.com/dexcom-g4-platinum-with-share-gets-fda-approval/ |access-date=March 2, 2023 |website=DiabetesInControl}}

The Dexcom G5 was approved in August 2015 by the FDA for use as a standalone device,{{Cite web|url=https://www.massdevice.com/dexcom-wins-fda-nod-for-g5-cgm/|title = Dexcom wins FDA nod for G5 CGM|date = 25 August 2015}} the G5 has Bluetooth integrated into its transmitter, enabling it to send data to a mobile device.{{Cite web|url=https://www.mobihealthnews.com/46291/dexcom-receives-fda-510k-clearance-for-bluetooth-enabled-cgm-g5|title = FDA approves Dexcom for Bluetooth-enabled CGM G5|date = 25 August 2015}} This allows for use of the device without the standalone receiver. The Dexcom G5 received a CE mark in September 2015.{{Cite web|url=https://medcitynews.com/2015/09/dexcom-gets-ce-mark-for-g5-continuous-glucose-monitor/|title = Dexcom gets CE Mark for G5 continuous glucose monitor|date = 14 September 2015}}

Dexcom went public in 2005 and is listed on the Nasdaq Global Select Market stock exchange under the ticker symbol DXCM. On April 20, 2020, Dexcom became a component of the Nasdaq-100, replacing American Airlines Group in the index.{{Cite press release |title=Dexcom, inc. to join the NASDAQ-100 Index beginning April 20, 2020 |url=https://www.nasdaq.com/press-release/dexcom-inc.-to-join-the-nasdaq-100-index-beginning-april-20-2020-2020-04-10 | publisher=Nasdaq | date=April 10, 2020}}

The Dexcom G7 was approved in December 2022 by the FDA for use as a standalone device and is the most accurate currently approved CGM in the U.S.{{Cite web|url=https://investors.dexcom.com/news/news-details/2022/Dexcom-G7-Receives-FDA-Clearance-The-Most-Accurate-Continuous-Glucose-Monitoring-System-Cleared-in-the-U.S/default.aspx|title = Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.|date = 8 December 2022}}

Awards and recognition

In October 2024, Time Magazine named Dexcom Stelo's over-the-counter glucose monitor one of the year's best inventions.{{Cite web |last=Klein |first=Jessica |date=2024-10-30 |title=Dexcom Stelo: the 200 Best Inventions of 2024 |url=https://time.com/7094684/dexcom-stelo/ |access-date=2024-11-02 |website=TIME |language=en}}

Partnerships

Dexcom entered into a partnership in 2015 with Google Life Sciences (which subsequently became Verily) to develop the Dexcom G7 {{Cite web |title= Fierce Biotech |url=https://www.fiercebiotech.com/medical-devices/updated-google-joins-forces-dexcom-for-miniaturized-glucose-monitor |access-date=2015-08-11 |website=fiercebiotech.com}}{{Cite web |title=Verily Life Sciences |url=https://verily.com/blog/one-of-the-smallest-most-discreet-continuous-glucose-monitoring-cgm-systems-receives-fda-clearance/ |access-date=2017-02-15 |website=verily.com}}{{Cite web |title=Dexcom G7 CGM - Powerfully simple diabetes management |url=https://www.dexcom.com/en-us/g7-cgm-system |access-date=2023-06-28 |website=Dexcom |language=en-US}}
Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its new G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps.{{Cite web|url=https://diatribe.org/fda-approval-tandems-tslim-integrated-dexcom-g4-platinum-cgm-expected-end-2015|title=FDA Approval of Tandem's t:slim with Integrated Dexcom G4 Platinum CGM Expected in 2015|date=7 August 2015}}{{cite web| url = https://www.medscape.com/viewarticle/850821| title = FDA Approves New Insulin Pump-Continuous Sensor Combo}} Tandem Diabetes Care received FDA approval in December 2019 for Control-IQ, a closed-loop technology that uses Tandem's t:slim X2 insulin pump and the Dexcom G6 "to automatically increase, decrease, or stop the delivery of insulin in response to the glucose levels of people with Type 1 diabetes."{{Cite web|url=https://www.theverge.com/2019/12/13/21020811/fda-closed-loop-insulin-system-software-diabetes-tandem-control-iq|title=FDA approves new closed-loop insulin delivery system for people with Type 1 diabetes|date=13 December 2019}}
In June 2019, Dexcom announced a collaboration with Companion Medical to enable the exchange of CGM data from Dexcom with insulin data from InPen into both companies' software applications.{{Cite web |date=June 7, 2019 |title=DexCom and Companion Medical Collaboration to Support CGM |url=https://finance.yahoo.com/news/dexcom-companion-medical-collaboration-support-122612930.html |access-date=March 2, 2023 |website=yahoo!finance}}
Dexcom entered into a partnership with Livongo, a digital chronic care management company, in January 2020 to share CGM data from the Dexcom G6 with Livongo's platform. This integration allowed Livongo to incorporate the CGM data along with other patient data.{{Cite web|url=https://www.fiercehealthcare.com/tech/jpm20-livongo-strikes-deal-dexcom-to-integrate-continuous-glucose-monitoring-data|title = JPM20: Livongo strikes deal with Dexcom to integrate continuous glucose monitoring data| date=14 January 2020 }}
In February 2020, Dexcom and Insulet Corporation signed a non-exclusive, global agreement to combine current and future Dexcom continuous glucose monitoring systems with Insulet's tubeless insulin delivery Pod into the Omnipod Horizon System for automated insulin delivery.{{Cite web|url=https://finance.yahoo.com/news/insulet-partners-dexcom-automated-insulin-123312537.html|title=Insulet Partners With Dexcom for Automated Insulin Delivery|date=February 24, 2020|website=Yahoo Finance}} This allowed the ability to adjust insulin doses based on Insulet's algorithm or through their smartphone.{{Cite web|url=https://www.mobihealthnews.com/news/insulets-omnipod-integrate-dexcom-abbott-cgms-automated-smartphone-controlled-dosing|title=Insulet's Omnipod to integrate with Dexcom, Abbott CGMS for automated, smartphone-controlled dosing|date=20 February 2020}}
The company also announced in March 2020 a partnership with Welldoc to integrate G6 CGM data with BlueStar, a digital platform for diabetes management.{{Cite web|url=https://www.mobihealthnews.com/news/dexcom-g6-integration-enables-insights-welldoc-bluestar-apples-rumored-video-workout-app-and|title = Dexcom G6 integration enables insights from Welldoc BlueStar, Apple's rumored video workout app and more digital health news briefs|date = 12 March 2020}}
In November 2024, Dexcom announced a "strategic partnership" and data exchange with Oura.{{Cite web |title=Dexcom and ŌURA Announce Strategic Partnership |url=https://investors.dexcom.com/news/news-details/2024/Dexcom-and-URA-Announce-Strategic-Partnership/ |access-date=2025-06-05 |website=investors.dexcom.com |language=en-US}}

Venture capital arm

In early 2021, Dexcom launched Dexcom Ventures, a venture capital arm focused on emerging continuous glucose monitoring technologies and devices measuring the levels of other types of substances and analytes.{{Cite web |last=Freeman |first=Mike |date=2021-02-13 |title=Dexcom unveils new corporate venture fund to invest in sensor, health monitoring startups |url=https://www.sandiegouniontribune.com/business/technology/story/2021-02-12/dexcom-unveils-corporate-venture-fund-to-invest-in-sensor-health-monitoring-startups |access-date=2024-04-15 |website=San Diego Union-Tribune |language=en-US}} In practice, Dexcom Ventures has also invested in cybersecurity platforms for the software used in medical devices.{{Cite web |last=MedCrypt |title=MedCrypt Extends Series B with Additional Investment from Dexcom Ventures |url=https://www.prnewswire.com/news-releases/medcrypt-extends-series-b-with-additional-investment-from-dexcom-ventures-301729017.html |access-date=2024-04-15 |website=www.prnewswire.com |language=en}}